NCT03205046 2021-01-06
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
Acerta Pharma BV
Phase 1/2 Terminated
Acerta Pharma BV
Samsung Medical Center
Samsung Medical Center
Samsung Medical Center
Queen Mary University of London